samedan logo
 
 
spacer
home > epc > winter 2001 > the trojan horse of oncology - the role of stealth drug delivery
PUBLICATIONS
European Pharmaceutical Contractor

The Trojan Horse of Oncology - The Role of Stealth Drug Delivery

The word 'cancer' instils fear into most people. One in four people will develop cancer at some point in their life and, given the dismal cure rates for most common cancers, many of those who are diagnosed with some form of the disease will eventually die of it. Fear is often augmented by the knowledge that the relentlessly growing cancer often brings with it pain, suffering and debility.

Far from being 'mindless' automatons, it has been shown that tumour cells employ numerous strategies to promote growth. Complicated mechanisms to switch on growth; vascular endothelial growth factors (VEGF) to create a blood supply as a pipeline to bring nutrients; and pumps such as p-Glycoprotein to get rid of ingested cellular toxins are some of the strategies that have evolved.

While the fight against cancer begins with prevention, once it has developed, permanent eradication of the disease requires all the skills oncologists can muster to outwit the tumour cell and the mechanisms it employs to ensure its continued cellular survival and tumour growth.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Peter Cheverton MBChB, MMed Rad(T), Director of Oncology for Daiichi Pharmaceuticals UK Ltd

Peter Cheverton is an Oncologist who spent 20 years in clinical practice before joining the pharmaceutical industry in 1990. He has worked for Lederle, ASTA Medica and has been Director of Oncology for Daiichi Pharmaceuticals UK Ltd for over three years. Peter works in European oncology development as part of the Daiichi Global Oncology Programme.

spacer
Dr Peter Cheverton
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Ultra slim and ultra quick


More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement